Knowthestock.com
BIOL - BIOLASE, Inc.

Sell

Weak GrowthEarnings/Profit is Negative

11%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -38.19%
Operating Income is Negative but improving
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -74.46%
Balance Sheet is WEAK
Current Asset to Current Liability Ratio is 1.09
Debt Ratio is 0.95
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.65
Cash Flow is WEAK
Cash from Operations is Negative
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
BIOLASE, Inc. (BIOL) - http://www.biolase.com
BIOLASE, Inc. is a medical device company, which engages in developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems uses a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems performs soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1987 and is headquartered in Irvine, CA.
Exchange - NASDAQ
Industry - Medical Specialties
Sector - Health Technology
CEO - Todd A. Norbe
Employees - 157
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.